Status:
COMPLETED
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the safety and efficacy of Xeloda, given in combination with standard chemotherapy regimens, for the first-line treatment of advanced and/or metastatic gastric cancer. All patie...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- advanced or metastatic gastric cancer;
- Eastern Cooperative Oncology Group (ECOG) \<=2.
Exclusion
- previous chemotherapy (except adjuvant or neoadjuvant treatment \>=6 months prior to study);
- evidence of central nervous system (CNS) metastasis;
- history of another malignancy within the last 5 years (except for successfully treated basal cell cancer of skin, or in situ cancer of the cervix);
- clinically significant cardiac disease.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00454636
Start Date
March 1 2007
End Date
July 1 2010
Last Update
September 29 2016
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcoy, Alicante, Spain, 03804
2
Ávila, Avila, Spain, 05071
3
Palma de Mallorca, Balearic Islands, Spain, 07014
4
Palma de Mallorca, Balearic Islands, Spain, 07198